JP6889661B2 - ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用 - Google Patents
４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用 Download PDFInfo
- Publication number
- JP6889661B2 JP6889661B2 JP2017536293A JP2017536293A JP6889661B2 JP 6889661 B2 JP6889661 B2 JP 6889661B2 JP 2017536293 A JP2017536293 A JP 2017536293A JP 2017536293 A JP2017536293 A JP 2017536293A JP 6889661 B2 JP6889661 B2 JP 6889661B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- arbitrary
- halo
- group
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCCN1CCN(*)CC1 Chemical compound CCCN1CCN(*)CC1 0.000 description 19
- WJJKCJYVIICABH-UHFFFAOYSA-N C(C1)CC1N1CCNCC1 Chemical compound C(C1)CC1N1CCNCC1 WJJKCJYVIICABH-UHFFFAOYSA-N 0.000 description 4
- HNZJIWIXRPBFAN-UHFFFAOYSA-N C(C1)C1N1CCNCC1 Chemical compound C(C1)C1N1CCNCC1 HNZJIWIXRPBFAN-UHFFFAOYSA-N 0.000 description 2
- VEPASEYGWRUBSU-QMMMGPOBSA-N C[C@@H](CNCC1)N1C1CCC1 Chemical compound C[C@@H](CNCC1)N1C1CCC1 VEPASEYGWRUBSU-QMMMGPOBSA-N 0.000 description 2
- MONSPSAJENVBMU-UHFFFAOYSA-N FC(C1)CC1N1CCNCC1 Chemical compound FC(C1)CC1N1CCNCC1 MONSPSAJENVBMU-UHFFFAOYSA-N 0.000 description 2
- QWQRRDJGWYYRSB-UHFFFAOYSA-N C(C1)CC1N(CC1)CCN1C1=NCCN1 Chemical compound C(C1)CC1N(CC1)CCN1C1=NCCN1 QWQRRDJGWYYRSB-UHFFFAOYSA-N 0.000 description 1
- JVHBUBQQFOFXFO-UHFFFAOYSA-N C(C1)CC1N1CC(CC2)NC2C1 Chemical compound C(C1)CC1N1CC(CC2)NC2C1 JVHBUBQQFOFXFO-UHFFFAOYSA-N 0.000 description 1
- OVLNTWCTBMENHF-UHFFFAOYSA-N CC(C)(C)C(CC1)=CC=C1c1cccc(C(F)(F)F)c1 Chemical compound CC(C)(C)C(CC1)=CC=C1c1cccc(C(F)(F)F)c1 OVLNTWCTBMENHF-UHFFFAOYSA-N 0.000 description 1
- RMTUDNLYRZAOKH-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1=NCCN1S(c(cc1)ccc1Br)(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1=NCCN1S(c(cc1)ccc1Br)(=O)=O)=O RMTUDNLYRZAOKH-UHFFFAOYSA-N 0.000 description 1
- VTQTYCRBJUSHOZ-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1SN1C(N2CCN(CC3CC3)CC2)=NCC1 Chemical compound CC(C)(C)c(cc1)ccc1SN1C(N2CCN(CC3CC3)CC2)=NCC1 VTQTYCRBJUSHOZ-UHFFFAOYSA-N 0.000 description 1
- NHCFVFYPYTWLLV-UHFFFAOYSA-N CC(C)(CC1)CC1N1CCN(C)CC1 Chemical compound CC(C)(CC1)CC1N1CCN(C)CC1 NHCFVFYPYTWLLV-UHFFFAOYSA-N 0.000 description 1
- CWFMLFDWMYRUJA-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(N(C1)C(N2CCNCC2)=NC1C1CC1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(N(C1)C(N2CCNCC2)=NC1C1CC1)(=O)=O CWFMLFDWMYRUJA-UHFFFAOYSA-N 0.000 description 1
- VUYZOGFJNKGKBB-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(N1C(N(CC2)CCN2C2CC(CO)C2)=NCC1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(N1C(N(CC2)CCN2C2CC(CO)C2)=NCC1)(=O)=O VUYZOGFJNKGKBB-UHFFFAOYSA-N 0.000 description 1
- WMUCTWTUVZDNEP-UHFFFAOYSA-N CC(CC1)CC1N1CCN(C)CC1 Chemical compound CC(CC1)CC1N1CCN(C)CC1 WMUCTWTUVZDNEP-UHFFFAOYSA-N 0.000 description 1
- VOZGXUBPIRWRMB-UHFFFAOYSA-N CC(CC1)CCC1N1CCN(C)CC1 Chemical compound CC(CC1)CCC1N1CCN(C)CC1 VOZGXUBPIRWRMB-UHFFFAOYSA-N 0.000 description 1
- MOPBMVCDOIOLBZ-UHFFFAOYSA-N CC1C(CN(CC2)CCN2I)C1 Chemical compound CC1C(CN(CC2)CCN2I)C1 MOPBMVCDOIOLBZ-UHFFFAOYSA-N 0.000 description 1
- VVKYUDUJAVQXMK-UHFFFAOYSA-N CC1C(CN2CCNCC2)C1 Chemical compound CC1C(CN2CCNCC2)C1 VVKYUDUJAVQXMK-UHFFFAOYSA-N 0.000 description 1
- QFIHLZZTOAFMDA-UHFFFAOYSA-N CCCN(CC1)CCN1I Chemical compound CCCN(CC1)CCN1I QFIHLZZTOAFMDA-UHFFFAOYSA-N 0.000 description 1
- RDKJCIWYMRHCHJ-YVMONPNESA-N CCCN(CCNC1=NCCN1[S+](C/C=C\c1c(C=S)cc[n]1C)(=O)=O)C1CCC1 Chemical compound CCCN(CCNC1=NCCN1[S+](C/C=C\c1c(C=S)cc[n]1C)(=O)=O)C1CCC1 RDKJCIWYMRHCHJ-YVMONPNESA-N 0.000 description 1
- HOMWFFAYDLGSTQ-UHFFFAOYSA-N CCN(CC1)CCN1C1=NCCN1 Chemical compound CCN(CC1)CCN1C1=NCCN1 HOMWFFAYDLGSTQ-UHFFFAOYSA-N 0.000 description 1
- BZFRKDRJLMMUHG-UHFFFAOYSA-N CCN(CC1)CCN1C1=NCCN1S(c(cccc1)c1C#N)(=O)=O Chemical compound CCN(CC1)CCN1C1=NCCN1S(c(cccc1)c1C#N)(=O)=O BZFRKDRJLMMUHG-UHFFFAOYSA-N 0.000 description 1
- FVQAKXVASFIKHR-UHFFFAOYSA-N CCN(CC1)CCN1C1=NCCN1S(c1cccc2n[o]nc12)(=O)=O Chemical compound CCN(CC1)CCN1C1=NCCN1S(c1cccc2n[o]nc12)(=O)=O FVQAKXVASFIKHR-UHFFFAOYSA-N 0.000 description 1
- TXIOGJHPPVXTOY-UHFFFAOYSA-N CCN1CCN(C)CC1 Chemical compound CCN1CCN(C)CC1 TXIOGJHPPVXTOY-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-O CCN1CC[NH2+]CC1 Chemical compound CCN1CC[NH2+]CC1 WGCYRFWNGRMRJA-UHFFFAOYSA-O 0.000 description 1
- LYQBZEGMENAKQE-SGDJNLEJSA-N CC[n]1ncc(S(N/C=C\N=C(/C)\N2CCN(CC)CC2)(=O)=O)c1C Chemical compound CC[n]1ncc(S(N/C=C\N=C(/C)\N2CCN(CC)CC2)(=O)=O)c1C LYQBZEGMENAKQE-SGDJNLEJSA-N 0.000 description 1
- NVSWQJOROBEHAC-UHFFFAOYSA-N CCc(cc1)ccc1-c1ccncc1 Chemical compound CCc(cc1)ccc1-c1ccncc1 NVSWQJOROBEHAC-UHFFFAOYSA-N 0.000 description 1
- ZFELWKKEFVPBJQ-UHFFFAOYSA-N CN1CCN(CCOC)CC1 Chemical compound CN1CCN(CCOC)CC1 ZFELWKKEFVPBJQ-UHFFFAOYSA-N 0.000 description 1
- IOEHGJOVFKXLCI-UHFFFAOYSA-N COc(cc1)ccc1C(N1C(N(CC2)CCN2C2CCC2)=NCC1)=O Chemical compound COc(cc1)ccc1C(N1C(N(CC2)CCN2C2CCC2)=NCC1)=O IOEHGJOVFKXLCI-UHFFFAOYSA-N 0.000 description 1
- DIJHXQXHKWBKHN-UHFFFAOYSA-N COc1cccc(C(N2C(N(CC3)CCN3C3CCC3)=NCC2)=O)c1 Chemical compound COc1cccc(C(N2C(N(CC3)CCN3C3CCC3)=NCC2)=O)c1 DIJHXQXHKWBKHN-UHFFFAOYSA-N 0.000 description 1
- MTIMDGQILFWMJI-UHFFFAOYSA-N CSC1=NCCN1 Chemical compound CSC1=NCCN1 MTIMDGQILFWMJI-UHFFFAOYSA-N 0.000 description 1
- OMVNKYKLQGVCAM-UHFFFAOYSA-N C[N+]1(C)C#[N]C(C2)C1C=CC2S(N1C(N(CC2)CCN2C2=CCC2)=NCC1)(=O)=O Chemical compound C[N+]1(C)C#[N]C(C2)C1C=CC2S(N1C(N(CC2)CCN2C2=CCC2)=NCC1)(=O)=O OMVNKYKLQGVCAM-UHFFFAOYSA-N 0.000 description 1
- DBGGJDWYVIWOIA-UHFFFAOYSA-N Cc(cc1)ccc1-c1ccc(C(F)(F)F)cc1 Chemical compound Cc(cc1)ccc1-c1ccc(C(F)(F)F)cc1 DBGGJDWYVIWOIA-UHFFFAOYSA-N 0.000 description 1
- ZZFKRTRYOSBWQY-UHFFFAOYSA-N Cc(cc1)ccc1-c1ccccc1O Chemical compound Cc(cc1)ccc1-c1ccccc1O ZZFKRTRYOSBWQY-UHFFFAOYSA-N 0.000 description 1
- KUZNURGIXXKBEJ-UHFFFAOYSA-N Cc(cc1)ccc1-c1cnccc1 Chemical compound Cc(cc1)ccc1-c1cnccc1 KUZNURGIXXKBEJ-UHFFFAOYSA-N 0.000 description 1
- DQQTZRXURVKTDD-IDKOKCKLSA-N NCCNC(CN1C2CNC[C@@H]1CC2)S Chemical compound NCCNC(CN1C2CNC[C@@H]1CC2)S DQQTZRXURVKTDD-IDKOKCKLSA-N 0.000 description 1
- NRVGSEJKKKWPJX-UHFFFAOYSA-N O=C(c(cc1)ccc1Cl)N1C(N(CC2)CCN2C2CCC2)=NCC1 Chemical compound O=C(c(cc1)ccc1Cl)N1C(N(CC2)CCN2C2CCC2)=NCC1 NRVGSEJKKKWPJX-UHFFFAOYSA-N 0.000 description 1
- OSSHYMWZUPKEBT-UHFFFAOYSA-N O=C(c1cc(Cl)ccc1)N1C(N(CC2)CCN2C2CCC2)=NCC1 Chemical compound O=C(c1cc(Cl)ccc1)N1C(N(CC2)CCN2C2CCC2)=NCC1 OSSHYMWZUPKEBT-UHFFFAOYSA-N 0.000 description 1
- MYJZSMHFHMMJGL-UHFFFAOYSA-N O=C(c1ccccc1Cl)N1C(N(CC2)CCN2C2CCC2)=NCC1 Chemical compound O=C(c1ccccc1Cl)N1C(N(CC2)CCN2C2CCC2)=NCC1 MYJZSMHFHMMJGL-UHFFFAOYSA-N 0.000 description 1
- UBXYXCRCOKCZIT-UHFFFAOYSA-N Oc1cccc(-c2ccccc2)c1 Chemical compound Oc1cccc(-c2ccccc2)c1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101933P | 2015-01-09 | 2015-01-09 | |
| US62/101,933 | 2015-01-09 | ||
| PCT/US2016/012588 WO2016112251A1 (en) | 2015-01-09 | 2016-01-08 | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501286A JP2018501286A (ja) | 2018-01-18 |
| JP2018501286A5 JP2018501286A5 (https=) | 2019-02-14 |
| JP6889661B2 true JP6889661B2 (ja) | 2021-06-18 |
Family
ID=55300775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536293A Expired - Fee Related JP6889661B2 (ja) | 2015-01-09 | 2016-01-08 | ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10202354B2 (https=) |
| EP (1) | EP3242875B1 (https=) |
| JP (1) | JP6889661B2 (https=) |
| CN (1) | CN107406418B (https=) |
| WO (1) | WO2016112251A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3242875B1 (en) | 2015-01-09 | 2022-02-23 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
| AU2016245434B2 (en) * | 2015-04-07 | 2020-10-29 | Ela Pharma Ltd | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto |
| WO2018132825A2 (en) * | 2017-01-16 | 2018-07-19 | Memorial Sloan Kettering Cancer Center | Treatment of sarcoma |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| PL179659B1 (pl) | 1994-07-21 | 2000-10-31 | Akzo Nobel Nv | Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ATE241986T1 (de) | 1997-05-06 | 2003-06-15 | Wyeth Corp | Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CN1278176A (zh) | 1997-11-06 | 2000-12-27 | 美国氰胺公司 | 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用 |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| CN101316823B (zh) * | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物 |
| EP2097386A2 (en) * | 2006-11-27 | 2009-09-09 | Novartis AG | Substituted dihydroimidazoles and their use in the treatment of tumors |
| US7897602B2 (en) * | 2009-01-12 | 2011-03-01 | Development Center For Biotechnology | Indolinone compounds as kinase inhibitors |
| EP2698367A1 (en) * | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
| ES2731773T3 (es) * | 2013-03-14 | 2019-11-19 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
| HRP20171609T1 (hr) * | 2013-03-15 | 2017-12-15 | Quanticel Pharmaceuticals Inc | Inhibitori histon demetilaze |
| EP3242875B1 (en) | 2015-01-09 | 2022-02-23 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
-
2016
- 2016-01-08 EP EP16702999.0A patent/EP3242875B1/en active Active
- 2016-01-08 WO PCT/US2016/012588 patent/WO2016112251A1/en not_active Ceased
- 2016-01-08 JP JP2017536293A patent/JP6889661B2/ja not_active Expired - Fee Related
- 2016-01-08 CN CN201680014129.5A patent/CN107406418B/zh not_active Expired - Fee Related
-
2017
- 2017-07-07 US US15/643,805 patent/US10202354B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107406418A (zh) | 2017-11-28 |
| US10202354B2 (en) | 2019-02-12 |
| JP2018501286A (ja) | 2018-01-18 |
| CN107406418B (zh) | 2021-10-29 |
| US20180022707A1 (en) | 2018-01-25 |
| WO2016112251A8 (en) | 2017-02-02 |
| WO2016112251A1 (en) | 2016-07-14 |
| EP3242875B1 (en) | 2022-02-23 |
| EP3242875A1 (en) | 2017-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7014765B2 (ja) | ピラゾロ化合物及びその使用 | |
| JP6783230B2 (ja) | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 | |
| JP6336598B2 (ja) | 抗増殖性化合物 | |
| JP6639497B2 (ja) | ブロモドメインインヒビターおよびその使用 | |
| JP6847844B2 (ja) | 治療用ピリダジン化合物およびその使用 | |
| JP6669745B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| JP6669744B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| JP6814730B2 (ja) | 治療用化合物およびその使用 | |
| JP6659703B2 (ja) | ピリダジノン誘導体および癌の処置におけるそれらの使用 | |
| TW201605857A (zh) | Ｃｄｋ８之醫療性抑制劑及其用途 | |
| JP6889661B2 (ja) | ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用 | |
| JP6855379B2 (ja) | 癌の処置のためのヒストンデメチラーゼｋｄｍ２ｂのインヒビターとしての（ピペリジン−３−イル）（ナフタレン−２−イル）メタノン誘導体および関連化合物 | |
| HK1247194A1 (en) | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors | |
| HK1247194B (zh) | 4，5-二氫咪唑衍生物及其作為組蛋白脫甲基酶(kdm2b)抑制劑的用途 | |
| HK1247198B (en) | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives as inhibitors of the histone demethylase kdm2b for the treatment of cancer | |
| HK1226056B (zh) | 吡唑並化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190107 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190107 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200717 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201019 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210325 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210423 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210521 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6889661 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |